Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q4 EPS of ($0.21), $0.09 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $35.54 million versus the consensus estimate of $24.51 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.